Our data may suggest that RUNX1 mRNA delivery has potential for the treatment of not only OA but also RA, the pathogenesis of which is mediated by IL-1 beta52, although the ability of the present strategy to deliver mRNA to the synovial membrane must be further investigated. Here, RUNX1 is linked to rheumatoid arthritis.